Ivermectin, Plasmodium falciparum, Blood stages, In vitro activity, In vivo efficacy, Dose-escalation, Randomized, Double-blind, safety, Adverse events, Parasite reduction, Transmission, Antiparasitic effect, Lambaréné, Gabon, Parasite load reduction, Tolerability, Mosquitocidal effect
Fosmidomycin, N-substituted hydroxamic acids, 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DXR, IspC), non-mevalonate biosynthesis pathway, antiplasmodial activity, co crystal structures.